Evoke Pharma Q2 EPS $(0.56) Beats $(0.73) Estimate, Sales $1.13M Beat $1.10M Estimate
Portfolio Pulse from Benzinga Newsdesk
Evoke Pharma reported Q2 losses of $(0.56) per share, beating the analyst consensus estimate of $(0.73) by 23.29%. This is a 21.13% increase over losses from the same period last year. The company also reported quarterly sales of $1.13 million, beating the analyst consensus estimate of $1.10 million by 2.82%. This is a 144.91% increase over sales from the same period last year.
August 10, 2023 | 12:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evoke Pharma's Q2 results beat analyst estimates, with losses improving and sales increasing significantly YoY.
Evoke Pharma's better than expected Q2 results, with reduced losses and increased sales, are likely to have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100